Literature DB >> 18331804

Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice.

Malika Benbouzid1, Nada Choucair-Jaafar, Ipek Yalcin, Elisabeth Waltisperger, André Muller, Marie José Freund-Mercier, Michel Barrot.   

Abstract

Antidepressant drugs act mainly by blocking the noradrenaline and/or serotonin uptake sites and require a chronic treatment. Tricyclic antidepressants are among the first line treatments clinically recommended against neuropathic pain. As observed against depression, a chronic treatment is required for a therapeutic effect. However, both in depression-related and pain-related research in rodents, it is difficult to design models that reproduce the clinical conditions and are sensitive to chronic but not to acute treatment by antidepressant drugs. In this study, we used a murine neuropathic pain model induced by the unilateral insertion of a polyethylene cuff around the main branch of the sciatic nerve. This model induced a long-lasting ipsilateral mechanical allodynia. We evidenced that chronic, but not acute, treatment with the tricyclic antidepressants nortriptyline or amitriptyline suppressed the cuff-induced mechanical allodynia. On the contrary, fluoxetine, a selective serotonin reuptake inhibitor, remained ineffective. To understand which mechanism is recruited downstream in order to alleviate the allodynia, we tested the opioid receptor antagonist naloxone, the delta-opioid receptor antagonist naltrindole and the kappa-opioid receptor antagonist nor-BNI. We show that the therapeutic effect of notriptyline implicates the endogenous opioid system, in particular the delta- and the kappa-opioid receptors. For comparison, we tested the anticonvulsant gabapentin and showed that it alleviates neuropathic allodynia after 3 days of treatment. Naloxone had no effect on gabapentin therapeutic benefit, showing that antidepressants and anticonvulsants alleviate neuropathic allodynia through independent mechanisms. Our work provides a clinically relevant model to understand the mechanism by which chronic antidepressant treatment can alleviate neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18331804     DOI: 10.1016/j.ejpain.2008.01.010

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  18 in total

1.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

Authors:  Marta Peciña; Amy S B Bohnert; Magdalena Sikora; Erich T Avery; Scott A Langenecker; Brian J Mickey; Jon-Kar Zubieta
Journal:  JAMA Psychiatry       Date:  2015-11       Impact factor: 21.596

2.  Amitriptyline does not block the action of ATP at human P2X4 receptor.

Authors:  J A Sim; R A North
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.

Authors:  Cristiano R Jesse; Ethel A Wilhelm; Cristina W Nogueira
Journal:  Psychopharmacology (Berl)       Date:  2010-08-06       Impact factor: 4.530

4.  The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors.

Authors:  Maria C Olianas; Simona Dedoni; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Opioid Exposure Negatively Affects Antidepressant Response to Venlafaxine in Older Adults with Chronic Low Back Pain and Depression.

Authors:  Sarah T Stahl; Changgi Jung; Debra K Weiner; Marta Peciña; Jordan F Karp
Journal:  Pain Med       Date:  2020-08-01       Impact factor: 3.750

6.  κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain.

Authors:  Salim Megat; Yohann Bohren; Stephane Doridot; Claire Gaveriaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Ipek Yalcin; Michel Barrot
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.

Authors:  Yohann Bohren; Dzenan Karavelic; Luc-Henri Tessier; Ipek Yalcin; Claire Gavériaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Michel Barrot
Journal:  Eur J Pain       Date:  2009-12-28       Impact factor: 3.931

9.  Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment.

Authors:  Nada Choucair-Jaafar; Ipek Yalcin; Jean-Luc Rodeau; Elisabeth Waltisperger; Marie-José Freund-Mercier; Michel Barrot
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

10.  Catecholaminergic and opioidergic system mediated effects of reboxetine on diabetic neuropathic pain.

Authors:  Nazlı Turan Yücel; Özgür Devrim Can; Ümide Demir Özkay
Journal:  Psychopharmacology (Berl)       Date:  2020-01-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.